Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers in Immunotherapy of Melanoma
NCT05878977Recruiting
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab, ipilimumab and pembrolizumab in melanoma, sponsored by Institute of Oncology Ljubljana. Primary endpoint: Response prediction in first line immune checkpoint inhibitors treatment at 3 years. Started Oct 2022; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05878977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878977.